...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Pharmacological Research >Clinical efficacy and safety of telmisartan versus losartan and their effect on lipid profile in stage 1 hypertension: A randomized, double blind, 12 week trial
【24h】

Clinical efficacy and safety of telmisartan versus losartan and their effect on lipid profile in stage 1 hypertension: A randomized, double blind, 12 week trial

机译：替米沙坦与氯沙坦的临床疗效和安全性及其对1期高血压患者血脂谱的影响：一项随机，双盲，12周试验

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aim of this study was to compare the efficacy and safety of telmisartan and losartan and also to examine their effect on lipid profile in patients of stage 1 hypertension.Method: Sixty three stage 1 hypertensive patients were divided randomly into telmisartan and losartan group of 32 and 31 patients respectively. At baseline and 12 weeks, systolic (SBP) and diastolic blood pressure (DBP), blood sugar level (BSL), total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL), very low density lipoprotein (VLDL) and high density lipoprotein (HDL) were measured. Result: The primary finding of the present study was that telmisartan and losartan significantly decreased SBP and DBP at 12 weeks compared to baseline but there was no significant difference in reduction of blood pressure in between both groups. It was also observed that fasting blood sugar level, serum total cholesterol, triglyceride, VLDL, and LDL decreased significantly and HDL increased significantly (p <0.001) after 12 weeks of treatment in telmisartan group only. No serious adverse effects were reported during the study. Conclusion: It was observed that only telmisartan and not losartan significantly improved lipid profile at 12 weeks.
机译：这项研究的目的是比较替米沙坦和氯沙坦的疗效和安全性，并检查它们对1型高血压患者血脂谱的影响。方法：将63例1期高血压患者随机分为替米沙坦和氯沙坦组32和31例患者。在基线和第12周时，收缩压（SBP）和舒张压（DBP），血糖水平（BSL），总胆固醇（TC），甘油三酸酯（TG），低密度脂蛋白（LDL），极低密度脂蛋白（VLDL）测定高密度脂蛋白（HDL）。结果：本研究的主要发现是替米沙坦和氯沙坦与基线相比在第12周时显着降低了SBP和DBP，但两组之间的血压降低没有显着差异。还观察到仅在替米沙坦组治疗12周后，空腹血糖水平，血清总胆固醇，甘油三酸酯，VLDL和LDL显着降低，HDL显着升高（p <0.001）。研究期间未报告严重不良反应。结论：观察到仅替米沙坦而不是氯沙坦能在12周时显着改善脂质状况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号